• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characterization and Automatic Discrimination between Predominant Hypoperfusion and Hyperperfusion Stages of NPDR.非增殖性糖尿病视网膜病变主要低灌注和高灌注阶段的特征及自动鉴别
J Pers Med. 2024 Sep 14;14(9):977. doi: 10.3390/jpm14090977.
2
Deep Capillary Nonperfusion on OCT Angiography Predicts Complications in Eyes with Referable Nonproliferative Diabetic Retinopathy.OCT 血管造影上的深层毛细血管无灌注预测有可治疗的非增殖性糖尿病视网膜病变的眼部并发症。
Ophthalmol Retina. 2023 Jan;7(1):14-23. doi: 10.1016/j.oret.2022.06.018. Epub 2022 Jul 5.
3
Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?无糖尿病性黄斑水肿的非增殖性糖尿病视网膜病变管理的最新进展;是否存在范式转变?
J Ophthalmic Vis Res. 2022 Jan 21;17(1):108-117. doi: 10.18502/jovr.v17i1.10175. eCollection 2022 Jan-Mar.
4
Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images.基于超广角视网膜图像的糖尿病视网膜病变进展预测的自动化机器学习。
JAMA Ophthalmol. 2024 Mar 1;142(3):171-177. doi: 10.1001/jamaophthalmol.2023.6318.
5
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.增生性糖尿病性视网膜病变在糖尿病性视网膜病变患者中发展和进展的预测因素。
Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2.
6
Epidemiology of Diabetic Retinopathy at Eye Clinic Svjetlost Sarajevo: Two Years Retrospective Single Center Study.萨拉热窝斯韦特洛斯特眼科诊所糖尿病视网膜病变的流行病学:一项为期两年的回顾性单中心研究。
Mater Sociomed. 2019 Dec;31(4):290-293. doi: 10.5455/msm.2019.31.290-293.
7
Microaneurysm turnover is a predictor of diabetic retinopathy progression.微动脉瘤的出现与消失与糖尿病视网膜病变的进展有关。
Br J Ophthalmol. 2019 Feb;103(2):222-226. doi: 10.1136/bjophthalmol-2018-311887. Epub 2018 Apr 26.
8
Comparison of Widefield Laser Ophthalmoscopy and ETDRS Retinal Area for Diabetic Retinopathy.广角激光眼底镜检查与糖尿病视网膜病变早期治疗糖尿病性视网膜病变研究(ETDRS)视网膜区域的比较
Ophthalmol Sci. 2022 Jun 28;2(4):100190. doi: 10.1016/j.xops.2022.100190. eCollection 2022 Dec.
9
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.Protocol W 随机临床试验中玻璃体内注射阿柏西普预防糖尿病视网膜病变致盲性并发症的四年视觉结果。
JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029.
10
Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy.非散瞳超广角视网膜成像与散瞳标准 7 区域 35mm 摄影及视网膜专科医师检查在糖尿病视网膜病变评估中的比较。
Am J Ophthalmol. 2012 Sep;154(3):549-559.e2. doi: 10.1016/j.ajo.2012.03.019. Epub 2012 May 23.

引用本文的文献

1
Understanding nonproliferative diabetic retinopathy progression using noninvasive imaging.使用非侵入性成像技术了解非增殖性糖尿病视网膜病变的进展
Eye (Lond). 2025 Jul 11. doi: 10.1038/s41433-025-03901-3.

本文引用的文献

1
Patterns of Progression of Nonproliferative Diabetic Retinopathy Using Non-Invasive Imaging.应用无创成像技术观察非增殖性糖尿病视网膜病变的进展模式。
Transl Vis Sci Technol. 2024 May 1;13(5):22. doi: 10.1167/tvst.13.5.22.
2
Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging System.评估糖尿病视网膜病变血管成分的成像方式:更新分期系统的综述与共识
Ophthalmol Sci. 2023 Dec 10;4(3):100449. doi: 10.1016/j.xops.2023.100449. eCollection 2024 May-Jun.
3
Frontiers in diabetic retinal disease.糖尿病视网膜病变的前沿。
J Diabetes Complications. 2023 Feb;37(2):108386. doi: 10.1016/j.jdiacomp.2022.108386. Epub 2022 Dec 21.
4
Perspectives on diabetic retinopathy from advanced retinal vascular imaging.从高级视网膜血管成像角度看糖尿病视网膜病变。
Eye (Lond). 2022 Feb;36(2):319-327. doi: 10.1038/s41433-021-01825-2. Epub 2022 Jan 5.
5
Comparison of Different Metrics for the Identification of Vascular Changes in Diabetic Retinopathy Using OCTA.使用光学相干断层扫描血管造影(OCTA)比较用于识别糖尿病视网膜病变血管变化的不同指标
Front Neurosci. 2021 Nov 30;15:755730. doi: 10.3389/fnins.2021.755730. eCollection 2021.
6
Characterization of Risk Profiles for Diabetic Retinopathy Progression.糖尿病视网膜病变进展风险特征的描述
J Pers Med. 2021 Aug 23;11(8):826. doi: 10.3390/jpm11080826.
7
Optical Coherence Tomography Angiography in Diabetes.光学相干断层扫描血管造影术在糖尿病中的应用。
Asia Pac J Ophthalmol (Phila). 2021;10(1):20-25. doi: 10.1097/APO.0000000000000351.
8
Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?糖尿病性视网膜病变的微血管病变:对发病机制的理解有何启示?
Eye (Lond). 2009 Jul;23(7):1496-508. doi: 10.1038/eye.2009.108. Epub 2009 May 15.
9
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.拟议的国际临床糖尿病视网膜病变和糖尿病性黄斑水肿疾病严重程度分级标准。
Ophthalmology. 2003 Sep;110(9):1677-82. doi: 10.1016/S0161-6420(03)00475-5.
10
Subclassification of preproliferative diabetic retinopathy and glycemic control: relationship between mean hemoglobin A1C value and development of proliferative diabetic retinopathy.增殖前期糖尿病视网膜病变的亚分类与血糖控制:平均糖化血红蛋白A1C值与增殖性糖尿病视网膜病变发生之间的关系。
Jpn J Ophthalmol. 2001 Sep-Oct;45(5):523-7. doi: 10.1016/s0021-5155(01)00380-x.

非增殖性糖尿病视网膜病变主要低灌注和高灌注阶段的特征及自动鉴别

Characterization and Automatic Discrimination between Predominant Hypoperfusion and Hyperperfusion Stages of NPDR.

作者信息

Mendes Luís, Ribeiro Luísa, Marques Inês, Lobo Conceição, Cunha-Vaz José

机构信息

AIBILI-Association for Innovation and Biomedical Research on Light and Image, 3000-548 Coimbra, Portugal.

出版信息

J Pers Med. 2024 Sep 14;14(9):977. doi: 10.3390/jpm14090977.

DOI:10.3390/jpm14090977
PMID:39338230
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11433224/
Abstract

BACKGROUND/OBJECTIVES: Diabetic retinopathy (DR) is a common diabetes complication that can lead to blindness through vision-threatening complications like clinically significant macular edema and proliferative retinopathy. Identifying eyes at risk of progression using non-invasive methods could help develop targeted therapies to halt diabetic retinal disease progression.

METHODS

A set of 82 imaging and systemic features was used to characterize the progression of nonproliferative diabetic retinopathy (NPDR). These features include baseline measurements (static features) and those capturing the temporal dynamic behavior of these static features within one year (dynamic features). Interpretable models were trained to distinguish between eyes with Early Treatment Diabetic Retinopathy Study (ETDRS) level 35 and eyes with ETDRS levels 43-47. The data used in this research were collected from 109 diabetic type 2 patients (67.26 ± 2.70 years; diabetes duration 19.6 ± 7.26 years) and acquired over 2 years.

RESULTS

The characterization of the data indicates that NPDR progresses from an initial stage of hypoperfusion to a hyperperfusion response. The performance of the classification model using static features achieved an area under the curve (AUC) of the receiver operating characteristics equal to 0.84 ± 0.07, while the model using both static and dynamic features achieved an AUC of 0.91 ± 0.05.

CONCLUSION

NPDR progresses through an initial hypoperfusion stage followed by a hyperperfusion response. Characterizing and automatically identifying this disease progression stage is valuable and necessary. The results indicate that achieving this goal is feasible, paving the way for the improved evaluation of progression risk and the development of better-targeted therapies to prevent vision-threatening complications.

摘要

背景/目的:糖尿病视网膜病变(DR)是一种常见的糖尿病并发症,可通过如临床显著性黄斑水肿和增殖性视网膜病变等威胁视力的并发症导致失明。使用非侵入性方法识别有进展风险的眼睛有助于开发针对性疗法以阻止糖尿病视网膜疾病的进展。

方法

一组82个影像学和全身特征用于描述非增殖性糖尿病视网膜病变(NPDR)的进展。这些特征包括基线测量值(静态特征)以及那些捕捉这些静态特征在一年内的时间动态行为的特征(动态特征)。训练可解释模型以区分糖尿病视网膜病变早期治疗研究(ETDRS)35级的眼睛和ETDRS 43 - 47级的眼睛。本研究中使用的数据收集自109名2型糖尿病患者(67.26 ± 2.70岁;糖尿病病程19.6 ± 7.26年),并在两年多的时间里获取。

结果

数据特征表明NPDR从最初的灌注不足阶段发展到高灌注反应阶段。使用静态特征的分类模型在接收器操作特征曲线下面积(AUC)为0.84 ± 0.07,而使用静态和动态特征的模型AUC为0.91 ± 0.05。

结论

NPDR经历一个初始的灌注不足阶段,随后是高灌注反应阶段。表征并自动识别该疾病进展阶段是有价值且必要的。结果表明实现这一目标是可行的,为改善进展风险评估以及开发更好的针对性疗法以预防威胁视力的并发症铺平了道路。